BACKGROUND: The ageing of populations makes outcome monitoring among elderly cancer patients particularly important. PATIENTS AND METHODS: Using data from the population-based Cancer Registry of Saarland, we examined age-specific trends in 5-year relative survival from 1979 to 2003 for patients with 15 common cancers in Germany. Model-based period analysis was applied to estimate 5-year relative survival for four age groups (15-54, 55-64, 65-74, 75+) in the periods 1979-1983, 1984-1988, 1989-1993, 1994-1998, and 1999-2003. RESULTS: Overall, 5-year relative survival improved steadily from 42.2% in 1979-1983 to 56.7% in 1999-2003. From the youngest to the oldest age group, 5-year relative survival increased by 14.5, 12.1, 12.5, and 8.4 percent units, respectively, after adjusting for changes in the spectrum of cancer sites, and survival significantly improved for 10, 12, 11, and 5 cancer sites, respectively. The age gradient particularly increased for cancer sites with major progress in chemotherapeutic treatment regimens, such as ovarian cancer, non-Hodgkin's lymphoma and leukemia. CONCLUSIONS: Relative survival of cancer patients increased considerably for many forms of cancer in Germany from 1979 to 2003. Increases were much less pronounced among elderly patients, leading to an increasing age gradient in prognosis.
BACKGROUND: The ageing of populations makes outcome monitoring among elderly cancerpatients particularly important. PATIENTS AND METHODS: Using data from the population-based Cancer Registry of Saarland, we examined age-specific trends in 5-year relative survival from 1979 to 2003 for patients with 15 common cancers in Germany. Model-based period analysis was applied to estimate 5-year relative survival for four age groups (15-54, 55-64, 65-74, 75+) in the periods 1979-1983, 1984-1988, 1989-1993, 1994-1998, and 1999-2003. RESULTS: Overall, 5-year relative survival improved steadily from 42.2% in 1979-1983 to 56.7% in 1999-2003. From the youngest to the oldest age group, 5-year relative survival increased by 14.5, 12.1, 12.5, and 8.4 percent units, respectively, after adjusting for changes in the spectrum of cancer sites, and survival significantly improved for 10, 12, 11, and 5 cancer sites, respectively. The age gradient particularly increased for cancer sites with major progress in chemotherapeutic treatment regimens, such as ovarian cancer, non-Hodgkin's lymphoma and leukemia. CONCLUSIONS: Relative survival of cancerpatients increased considerably for many forms of cancer in Germany from 1979 to 2003. Increases were much less pronounced among elderly patients, leading to an increasing age gradient in prognosis.
Authors: Daniel A Hamstra; Kyounghwa Bae; Miljenko V Pilepich; Gerald E Hanks; David J Grignon; David G McGowan; Mack Roach; Colleen Lawton; R Jeffrey Lee; Howard Sandler Journal: Int J Radiat Oncol Biol Phys Date: 2011-03-31 Impact factor: 7.038
Authors: Vasileios Askoxylakis; Christian Thieke; Sven T Pleger; Patrick Most; Judith Tanner; Katja Lindel; Hugo A Katus; Jürgen Debus; Marc Bischof Journal: BMC Cancer Date: 2010-03-22 Impact factor: 4.430
Authors: Sven Mahner; Gülten Oskay-Özcelik; Elke Heidrich-Lorsbach; Stefan Fuxius; Harald Sommer; Peter Klare; Antje Belau; Birgit Ruhmland; Thomas Heuser; Heinz Kölbl; Susanne Markmann; Jalid Sehouli Journal: J Cancer Res Clin Oncol Date: 2012-04-15 Impact factor: 4.553